

FAN1 controls CAG repeat expansion in Huntington's disease by dual functions, MLH1 retention and nuclease activity

Rob Goold, Joseph Hamilton, Thomas Menneteau, Michael D. Flower, Emma L. Bunting, Sarah G. Aldous, Antonio Porro, José R. Vicente, Nicholas D. Allen, Hilary Wilkinson, Gillian P. Bates, Alessandro A. Sartori, Konstantinos Thalassinou, Gabriel Balmus, Sarah J. Tabrizi

Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, WC1N 3BG, UK



Background

Somatic expansion in Huntington's disease is a pathogenic phenomenon whereby the CAG trinucleotide repeat in exon 1 of the *HTT* gene expands throughout an individual's lifetime. This occurs via the mismatch repair (MMR) pathway, requiring key proteins MSH3 and MLH1, involved in excising DNA loop-outs.




Figure 1. Manhattan plot showing individual SNPs in DNA repair genes identified as modifiers of HD age at onset (adapted from GeM-HD Consortium, 2019)

Recent GWAS evidence highlighted the DNA repair gene *FAN1* as a HD-modifier (1), which acts by suppressing somatic expansion (2). This project establishes the mechanism by which *FAN1* stabilises the *HTT* CAG repeat.

Results (I)

FAN1 binds MLH1 via residues ¹²⁶SPYF¹²⁹, reducing somatic expansion

A genetic analysis identified an evolutionary conserved motif, ¹²⁶SPYF¹²⁹, resembling an MLH1-interacting protein (MIP)-box found in known MLH1-interactors such as MSH3. Mutation of these residues essentially abolished the *FAN1*-MLH1 interaction and reduced somatic expansion (Fig. 3)





Figure 3. (a) GFP-Trap pulldown of *FAN1* in U2OS cells showed reduced MLH1-binding after mutation of ¹²⁶SPYF¹²⁹ residues. (b) Mutation of ¹²⁶SPYF¹²⁹ residues reduced somatic expansion significantly, although not as pronounced as *FAN1*^{-/-} cells.

FAN1's nuclease domain accounts for residual stability mechanism

FAN1's nuclease domain was inactivated through the D960A mutation. In concert with mutation of the MIP-box (F129A), this produced a somatic expansion rate equivalent to *FAN1*^{-/-} cells (Fig. 4)

Figure 4. Somatic expansion rates in U2OS cells expressing *FAN1* variants with MLH1-binding mutation F129A and nuclease-dead mutation D960A.



Methods

The *FAN1*^{-/-} U2OS osteosarcoma model allows the effects of *FAN1* variants on somatic expansion and DNA repair protein interactions to be assessed (Fig. 2).




Figure 2. *FAN1*^{-/-} U2OS cell model featuring a Flp-In locus for complementation with GFP-tagged *FAN1* variants. Cells are co-transduced with a 118Q *HTT* exon 1 construct.

Somatic expansion was measured by fragment analysis: CAG repeat tracts were PCR-amplified with fluorescent forward primers and resolved by capillary electrophoresis.

Results (II)

FAN1-MLH1 binding reduces somatic expansion by limiting mismatch repair

FAN1 knockdown in 125 CAG medium spiny neurons (MSNs) promoted a greater MSH3-MLH1 interaction, known to drive somatic expansion through MMR activity (Fig. 5a). Concurrently, MIP-box *FAN1* mutants showed reduced viability in a 6-thioguanine assay, indicative of increased mismatch repair (Fig. 5b).




Figure 5. (a) MLH1 IP in 125 CAG MSNs showed greater MSH3-MLH1 binding in the absence of *FAN1*. (b) Mutation of ¹²⁶SPYF¹²⁹ residues in U2OS cells reduced viability in 6-thioguanine assay, suggestive of greater MMR activity.

Conclusions

FAN1 stabilizes the *HTT* CAG repeat by MLH1 sequestration from the MMR pathway and nuclease activity (Fig. 6). Promoting this interaction may alter pathology and the impact of doing so will be subsequently examined in physiologically-relevant HD systems.




Figure 6. Proposed mechanism of *FAN1* in limiting somatic expansion at the CAG repeat

References

- GeM-HD Consortium (2019) CAG repeat not polyglutamine length determines timing of Huntington's disease onset. *Cell*, 178, 887-900 e14.
- Goold R, Flower M, Hensman-Moss D, Medway C, Wood-Kaczmar A, Andre R, Farshim P, Bates GP, Holmans P, Jones L, Tabrizi SJ (2018) *FAN1* modifies Huntington's disease progression by stabilising the expanded *HTT* CAG repeat. *Hum Mol Genet* 0: 1-12